Arguments in favor of remdesivir for treating SARS-CoV-2 infections
Wen-ChienKo, Jean-MarcRolain, Nan-YaoLee, Po-LinChen, Ching-TaiHuang, Ping-IngLee, Po-RenHsueh
Show more
https://doi.org/10.1016/j.ijantimicag.2020.105933
1. Introduction
Since the end of 2019, the increasing number cases of pneumonia were reported in Wuhan, then other cities and provinces in China and many countries [1], [2], [3], [4], [5], [6], [7], and the 2019 novel coronavirus (2019-nCoV) or severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [8], a new human pathogen, was identified as the cause of Wuhan pneumonia. The disease spectrum of SARS-CoV-2 infection, so called Coronavirus Disease 2019 (COVID-19), was known to be diverse in severity, ranging from asymptomatic carriage, mild respiratory tract infection to severe or fatal pneumonia. Moreover, SARS-CoV-2 can be transmitted within the family, in the community, among cruise passengers, and in hospitals, and has become a public health emergency of international concern, declared by WHO on January 30, 2020.
